Navigation Links
first in Biological Technology

Novavax Reports Second Quarter 2009 Financial Results

... compared to December 31, 2008. Since the first quarter, Novavax continued to advance its vaccine ... Specific accomplishments since the first quarter included the following: ... Control. "Our progress since the first quarter has been transformational," said Novavax ...

Catalyst Pharmaceutical Partners Reports Second Quarter 2009 Financial Results

... for the same period in 2008. Results for the first six months of 2009 included non-cash charges ... were $3,698,885 compared to $2,986,503 for the first six months of 2008, including non-cash ... General and administrative expenses for the first six months of 2009 totaled $1,114,470 compared to ...

Synthetech Reports First Quarter Fiscal 2010 Results

... NZYM) today announced financial results for the first quarter of fiscal 2010, which ended June 30, ... compared to revenue of $4.9 million in the first quarter of fiscal 2009. Operating income for the ... or $0.07 per basic share, compared to last year's first quarter net income of $295,000, or $0.02 per ...

InterMune Reports Second Quarter 2009 Financial Results and Business Highlights

... that positions us for potential approval in the first review cycle. Our Marketing Authorization ... expect to submit the MAA for pirfenidone in the first quarter of 2010." Mr. Welch continued, ... that our partner Roche will enroll the first patient in our Phase 2b study of ITMN-191 in ...

SEQUENOM Reports Second Quarter 2009 Financial Results and Highlights

... Six-Month Results Revenue for the first six months of 2009 totaled $17.9 million, compared with $23.4 million for the first six months of 2008. Cost of product and services revenues for the first six months of 2009 was $6.6 million, compared ...

OncoGenex Reports Second Quarter 2009 Financial Results

... due to manufacturing costs incurred in the first six months of 2009 associated with the ... takeover of Sonus. Reducing the expenses in the first six months of 2008 was a Scientific Research and ... to provide a business update and discuss the first quarter results. A live webcast will be available ...

Telik Announces Second Quarter 2009 Financial Results

... June 30, 2008. Total operating expenses for the first six months of 2009 were $14.0 million, compared with $21.6 million for the first six months of 2008. Operating expenses in the first six months of 2009 included approximately $1.3 ...

Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2009

... second quarter of 2008 and 4% as compared to the first quarter of 2009. Excluding the impact of foreign ... increased by approximately 2% as compared to the first quarter of 2009. Excluding the impact of foreign ... did not have an impact on the change from the first quarter of 2009. The decline in our Base ...

Repligen Reports First Quarter Fiscal Year 2010 Financial Results

... (Nasdaq: RGEN ) today reported results for the first quarter fiscal year 2010, ended June 30, 2009. ... compared to total revenue of $13,660,000 for the first quarter of fiscal year 2009. The prior year ... the April 2008 patent licensing agreement. Total first quarter fiscal year 2010 revenue was comprised of ...

PDI Reports 2009 Second Quarter Financial Results

... PDI, Inc., stated, "While we recognize that the first half of the year has been difficult, with ... and $10.3 million for the second quarter and first six months, respectively, we are working ... strategic shift in outsourced sales, the first half of 2009 was particularly challenging for our ...

Cadence Pharmaceuticals Reports Second Quarter 2009 Financial Results

... of 12,039,794 shares of common stock during the first quarter of 2009 pursuant to a private placement ... direct offering of common stock during the first quarter of 2008. The per share amounts for three ... pursuant to a private placement in the first quarter of 2009 and 9,240,307 shares of ...

GeoVax Labs, Inc. Provides Clinical Studies Update

... begin this trial, assuming FDA approval, in the first quarter of 2010." Preventative Clinical ... to Phase 2 is a significant step for GeoVax. The first injections for the Phase 2a trial were conducted ... trial will be conducted locally in Atlanta. This first step will be a safety trial using intensive ...

Shire plc: Core Portfolio of Products Delivers 20% Sales Growth

... control in children aged 6 to 12 from the first time point measured (1.5 hours) through 13 hours post-dose. VYVANSE is now the first and only oral ADHD stimulant treatment to ... as they become available. Results from the first of the three Phase 3 trials were positive, ...

Genomic Health Announces Second Quarter 2009 Financial Results and Business Progress

... million, compared with $51.2 million for the first six months of 2008. Product revenue for the six ... million, compared with $49.7 million for the first six months of 2008. Net loss for the six ... $8.6 million, compared with $10.7 million for the first six months of 2008. Basic and diluted net loss ...

Revised: Sinovac Provides Update on Clinical Trial for H1N1 Vaccine Trials

... well. All of the volunteers received their first shot of the vaccine and, during the three day ... 404 juvenile and 403 children, had received the first shot of the vaccine through July 25. During the ... the Beijing municipal government(1) made its first purchase of Panflu from Sinovac, with an initial ...

Hoya Announces First Quarter Financial Results for FY2010

... today announced financial results for the first quarter ended June 30, 2009. Net sales were 94.9 ... ended March 31, 2009. Net income for the first quarter was down 81.8%, to 3.8 billion ... to the preceding quarter." For the first six months of FY2010 ending September 30, 2009, ...

Purdue Pharmaceutical Products L.P. and Transcept Pharmaceuticals, Inc. Sign Exclusive Agreement to Commercialize Intermezzo(R) in the United States

... Intermezzo ((R)) has the potential to be the first prescription sleep aid specifically approved for ... under the co-promotion option as early as the first anniversary of the commercial launch of ... sublingual tablet) has the potential to be the first prescription sleep aid specifically approved for ...

America's Organic Home-Fueling Movement Begins in Los Angeles

... Green Celebrities Attend World's first E-Fuel MicroFuelerTM Installation ... of filling up your tank at home has arrived! The first of the revolutionary portable home micro-refinery ... California. GreenHouse introduced the first E-Fuel MicroFueler TM at a premier debut event ...

ERT Reports Second Quarter 2009 Results

... million a year ago and $23.8 million for the first quarter of 2009. Gross margin percentage ... compared to 57.0% a year ago and 50.4% for the first quarter of 2009. Operating income margin ... compared to 30.3% a year ago and 14.0% for the first quarter of 2009. Net income was $2.5 ...

Anadys Pharmaceuticals Reports Second Quarter 2009 Financial Results and Program Highlights

... treatment. We look forward to receiving the first data from this trial by year-end 2009 and additional data in the first half of 2010." Financial Results ... group by year-end and additional data during the first half of 2010; (v) expectations regarding the ...

Mylan Reports Adjusted Diluted EPS of $0.32 for the Quarter Ended June 30, 2009

... "On the strength of the momentum provided by our first half results, coupled with what we now forecast ... (Divalproex), which Mylan launched in the first quarter of 2009. Total revenues from ... unfavorable impact of generic competition, which first entered the market in 2007. Matrix ...

Sangamo BioSciences Reports Second Quarter 2009 Financial Results

... 30, 2008. Revenues were $7.9 million for the first half of 2009, compared to $5.6 million in the ... operating expenses were $20.1 million for the first half of 2009 and $22.4 million in the first half of 2008. The decrease in operating expenses ...

Neurocrine Biosciences Reports Second Quarter 2009 Results

... $9.0 million, compared to $13.0 million for the first half of 2008. We incurred a $2.2 million restructuring charge in the first half of 2008 compared to a $0.7 million charge in the first half of 2009. Additionally, other non-personnel ...

BP and Verenium Announce Vercipia Biofuels to Advance the Commercialization of Cellulosic Ethanol

... focus on the development of one of the nation's first commercial-scale cellulosic ethanol facilities, ... next two years as we move toward bringing a first commercial facility into production," said Carlos ... of technology being developed under the first phase of the BP-Verenium partnership and brings ...

Sunesis Reports Financial Results for the Second Quarter 2009

... for the second quarter and $10.2 million for the first half of 2009. As of June 30, 2009, cash, cash ... 10 to 15 percent. In the Bolus Schedule, both first relapse and primary refractory patients are ... General and administrative expenses for the first three and six months of 2009 were $2.0 million ...

Marinus Pharmaceuticals Adds Two Life Sciences Veterans to its Board of Directors

... obtain FDA approval for Tetrabenazine (TBZ), the first drug ever licensed in the United States to treat ... a company with positive phase 2a data for a novel first in class antiepileptic drug that will address ... allopregnanolone. It is being investigated as a first in class treatment for epilepsy. Ganaxolone has ...

Sanofi-aventis Announces Second Quarter 2009 Results

... selected items. Consolidated net income for the first half of 2009 was euro 2,637 million, versus euro 2,335 million for the first half of 2008. Consolidated earnings per share for the first half of 2009 was euro 2.02, against euro 1.78 for ...

Seasoned Dermatologist Nissan Pilest of Irvine, CA, Joins SDS Clinical Trials as Clinical Investigator for Dermatology Division

... said Dr. Pilest. "To be among the first to benefit from the newest drug and devise ... is given. If my enrolled patients can be the first to experience a new solution, then that makes my ... experience spanning more than 30 years. He is a first level trainer for the Fraxel Repair CO2 ...

Cynosure Reports Second Quarter 2009 Financial Results

... the same period of 2008 and $14.8 million in the first quarter of 2009. The decline from the second ... aesthetic laser industry. The increase from the first quarter of 2009 reflected a strengthening ... for the same period of 2008 and 60.9% in the first quarter of 2009. The decline in gross margin in ...

GreenHouse Debuts the World's First E-Fuel MicroFuelerTM in Los Angeles

... a high performance ethanol fuel for cars. The first installation of the E-Fuel MicroFueler will be ... for the unit. "With the launch of the first operational MicroFueler in Los Angeles, ... Visuals Will Include: Debut of the first MicroFueler Hollywood locals fueling their cars ...

Histogen Hair Regrowth Clinical Trial Presented at ISHRS Annual Meeting

... HSC human hair regrowth product for the first time at the International Society of Hair ... proteins, growth factors and contains the first naturally stabilized, bioactive solution of Wnt ... from existing follicles. Histogen's trial is the first demonstration that compounds containing bioactive ...

UCR scientists manipulate ripples in graphene, enabling strain-based graphene electronics

... Ning (Jeanie) Lau and colleagues now report the first direct observation and controlled creation of ... predicted theoretically, but Lau's lab is the first to demonstrate and quantify the phenomenon ... the ripples in graphene sheets represents the first step towards strain-based graphene engineering. ...

FDA Grants First Authorization of a Commercial 2009 H1N1 Flu Test for use During Pandemic Flu Emergency to Quest Diagnostics' Focus Diagnostics Business

... A H1N1 (2009) Real Time RT-PCR test is the first commercial lab test to be granted an emergency ... for the 2009 H1N1 influenza virus. It is also the first test to qualitatively detect RNA of the pandemic ... Focus business, which has a track record of being first to market with new laboratory testing services ...

Sigma-Aldrich (Nasdaq:SIAL) Reports Q2 2009 Diluted EPS of $0.68; YTD Diluted EPS up 1.5% to $1.36. Full Year 2009 Guidance Reaffirmed, With 2009 Diluted EPS Expected to Exceed 2008's $2.65.

... a 1.5% increase from the $1.34 reported for the first six months of 2008. Excluding the negative ... and 19.4% increase for the second quarter and first six months of 2009, respectively. A ... for all of 2009, believing that we can repeat our first half performance for the remainder of the year, ...

Study Published in Child and Adolescent Psychiatry and Mental Health Demonstrated Once-Daily Vyvanse(R) (lisdexamfetamine dimesylate) CII Provided Significant Improvement of ADHD Symptoms for Children at 13 Hours After Administration

... Disorder (ADHD) in children aged 6 to 12 from the first time point measured (1.5 hours) up to the last ... Irvine. "These published data are the first to have shown duration of effect of an oral ADHD ... improvement in children aged 6 to 12 from the first time point measured (1.5 hours) up to 13 hours ...

Human Genome Sciences Announces New Order for Raxibacumab (ABthrax(TM)) from U.S. Government

... a first-in-class treatment for anthrax, and the first procurement under Project BioShield of a product ... 2009, HGS fulfilled its commitment to deliver the first 20,000 doses of raxibacumab to the Strategic ... HGS recognized $153.8 million in revenue in the first quarter of 2009 from ...

Axial Biotech Enters Partnership with the University of Utah to Utilize the Utah Population Database to Develop Personalized Diagnostic Tests for Spine Disorders

... for the ScoliScore(TM) AIS Prognostic Test - the first test to determine the risk of progressive ... the risk of developing severe scoliosis and the first molecular diagnostic for a spine disorder. GenDB ... the ScoliScore(TM) AIS Prognostic Test, the first and only test that utilizes the genetic blueprint ...

Schering-Plough Reports Financial Results for 2009 Second Quarter

... was also launched in Canada in June as the first once-monthly subcutaneous treatment; ... and In Animal Health, the launch of the first vaccine against canine influenza virus, which was ... that a single injection of corifollitropin alfa, first in the class of sustained follicle stimulants, ...

Wyeth Announces Stockholder Approval of Pfizer Merger at 2009 Annual Meeting

... of 2%." Wyeth also reported solid first quarter 2009 results, confirming that its ... by geography, the Company generated 52% of its first quarter revenue outside the United States and 60% of its first quarter revenue from non-traditional ...

OpenQ Posts a 200% Revenue Growth in the First Half of 2009

... OpenQ announces solid revenue growth for the first half of 2009 and is now serving 7 of the Top 10 ... posted a phenomenal 200% revenue growth in the first half of 2009 as compared to the same time last year. The exceptional first half results were driven primarily by new ...
Other Contents
(Date:7/24/2014)... soup in which life arose have been maintained in our ... Anglia. , Research published today in the Journal of ... very likely also in animals still perform ancient reactions thought ... some four billion years ago. , The primordial soup theory ... a result of the combination of metals, gases from the ...
(Date:7/24/2014)... in German . ... asthma sufferers worldwide, a further 600 million people living ... global population contending with allergic rhinitis (allergic inflammation of ... other organs and parts of the body beyond the ... the form of inflammatory bowel diseases such as colitis ...
(Date:7/24/2014)... doctors and scientists from Singapore have developed Asia,s first ... eye disease that affects the cornea called corneal stromal ... vision. , Called the POLARIS TGFBI (Transforming Growth ... to aid in the diagnosis and management of patients ... members carrying a TGFBI mutation who may also be ...
Breaking Biology News(10 mins):New drugs to combat asthma and the like 2New drugs to combat asthma and the like 3Singapore team develops Asia's first genetic test that can prevent corneal blindness 2Singapore team develops Asia's first genetic test that can prevent corneal blindness 3
(Date:7/24/2014)... 24, 2014 Just as fitness and ... consider their own financial and marketing strength to be ... campaigns to the next level by using the most ... IVR, Voice Broadcast, Call Tracking and SMS texting ... rate, text messages are quickly become integral in marketing ...
(Date:7/24/2014)... CarePoint Health is proud to ... oncology, Dr. Hitendra Upadhyaya, has joined our network, ... Upadhyaya to the community. Hundreds of highly skilled ... a comprehensive network of top doctors and practices ... specialties. This latest acquisition represents CarePoint Health’s commitment ...
(Date:7/24/2014)... of Medicine researchers may have found a way to ... that pre-treatment of neurons with the anti-aging protein Klotho ... toxic amyloid protein and glutamate. These findings currently appear ... , Alzheimer,s disease is the most frequent age-related dementia ... age 65 and older and more than 40 percent ...
(Date:7/24/2014)... -- Drinking caffeine may worsen the hot flashes and ... they go through menopause, new survey data suggests. ... limiting caffeine intake may be useful for those postmenopausal ... said researcher Dr. Stephanie Faubion, director of the Women,s ... But caffeine -- a stimulant found in coffee ...
(Date:7/24/2014)... Bonheur Children,s Hospital and the University of Tennessee Health ... a new drug shown to safely reduce the viral ... infected with respiratory syncytial virus (RSV). RSV is the ... young children in the United States and worldwide. ... Disease Specialist John DeVincenzo, MD. DeVincenzo,s Le Bonheur lab ...
Breaking Medicine News(10 mins):Health News:Pump Up Your Gym’s Marketing Muscles with Mobile Marketing: CallFire's Health & Fitness Webinar Week – July 28th to August 1st 2Health News:Pump Up Your Gym’s Marketing Muscles with Mobile Marketing: CallFire's Health & Fitness Webinar Week – July 28th to August 1st 3Health News:Dr. Upadhyaya Joins CarePoint Health Medical Group 2Health News:BU researchers discover that Klotho is neuroprotective against Alzheimer's disease 2Health News:Is Coffee Aggravating Your Hot Flashes? 2Health News:RSV research breakthrough to help infected children 2
Other TagsOther Tags